OTTAWA, ON – CSL Behring Canada announced that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), is now available in all of Canada. HAEGARDA is a subcutaneous C1 esterase inhibitor (C1-INH) therapy indicated for routine prevention of Hereditary Angioedema (HAE) attacks in adolescent and adult patients.1 HAE patients have absent or low levels of endogenous or...
Latest News
Jackson Center, PA – Halberd Corporation (OTC-PINK: “HALB“) received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome. Cockayne Syndrome is a fatal autosomal recessive neurodegenerative disorder which causes premature aging and severely impaired development...
SAN DIEGO, CA — Halozyme Therapeutics, Inc., today announced that argenx received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) injection co-formulated with Halozyme’s ENHANZE® drug delivery technology for subcutaneous (SC) use for the treatment of adult patients with generalized myasthenia gravis...
SAN DIEGO, Calif. — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that Takeda received European Commission (EC) approval for HYQVIA® [Immune Globulin Infusion 10% (Human)] co-formulated with Halozyme’s ENHANZE® drug delivery technology as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy (CIDP) after stabilization with intravenous...
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China – Harbour BioMed (“HBM”, HKEX: 02142) today announced positive topline results from its Phase 2 proof-of-concept clinical trial of batoclimab (HBM9161) in Chinese generalized myasthenia gravis (gMG) patients. Data received from the Phase 2 Study, as the first clinical evidence of anti-FcRn therapies in Chinese patients, showed...
In partnership with the Children’s Hospital of Wisconsin and the Genomic Sciences and Precision Medicine Center (GSPMC) at Medical College of Wisconsin (MCW) and sponsored by Orchard Therapeutics, Rare Storytellers Presents: Women and Rare Disease! More than 7,000 rare diseases collectively impact over 350,000,000 people worldwide. Sharing songs and stories unite a strong voice for all...
PLYMOUTH MEETING, Pa., March 19, 2021 — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced publication of a white paper sharing outcomes from a Summit on Sleep...
PLYMOUTH MEETING, PA. — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome (PWS). “The decision to grant Orphan Drug designation to pitolisant indicates that it could be a promising treatment option...
Chicago, Ill. – Scientists at Harvard University and the University of Illinois Chicago have developed an antibiotic that could give medicine a new weapon to fight drug-resistant bacteria and the diseases they cause. The antibiotic, cresomycin, described in Science, effectively suppresses pathogenic bacteria that have become resistant to many commonly...
BELGAUM — He is a big challenge for the medical field. A handicapped boy having innumerous fractures in his body, has been preparing to participate at the national-level swimming competition. Mohin Mustaque Junned, a 12-year-old boy is suffering from a rare disease that causes zero bone calcium. It is called...